Rhiannon Coulson

Peter MacCallum Cancer Centre — Australia

Medicine · Health Sciences

10h-index737citations45works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Breast Cancer Therapies(36), Cancer-related Molecular Pathways(32), Microtubule and mitosis dynamics(19), Estrogen and related hormone effects(6), Lung Cancer Treatments and Mutations(3)

Publications45 total

Abstract GS3-06: Rb Functions as a Transcriptional Activator of ER Targets Following CDK4/6 Inhibition in Luminal Breast Cancer
Clinical Cancer Research·2026
Correction: INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Cancer Discovery·2025Open Access
Supplementary Table 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2025Open Access
Supplementary Table 1 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2025Open Access
Supplementary Figures 1-14 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2025Open Access
Supplementary Synthetic Methods from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2025Open Access
Tumor Biomechanics Alters Metastatic Dissemination of Triple Negative Breast Cancer via Rewiring Fatty Acid Metabolism
Advanced Science·2024· 19 citedOpen Access
Supplementary Synthetic Methods from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024· 1 citedOpen Access
Figure 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Supplementary Synthetic Methods from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Supplementary Table 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Figure 3 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Data from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024· 3 citedOpen Access
Figure 3 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Supplementary Figures 1-14 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Figure 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Figure 6 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Figure 5 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Figure 5 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
Figure 4 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
2024Open Access
page 1 of 3Next →

Frequent Co-authors

April C. Watt(29), Shom Goel(29), Catherine Dietrich(29), Antonio Ahn(29), Michael Taylor(29), Krutika Ambani(29), Kun‐Hui Lu(29), Catherine Blyth(29), Susanne Ramm(29), Alec Trub(28), Keefe T. Chan(28), Christabella A. Mahendra(28), Sunil Kumar Matsa(28), John Bisi(28), Jay C. Strum(28), Patrick J. Roberts(28), Elgene Lim(11), Neil Portman(8), Heloisa Milioli(8), Aliza Yong(8)